Verdence Capital Advisors’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $306K | Buy |
1,418
+4
| +0.3% | +$765 | 0.02% | 537 |
|
|
2026
Q1 | $259K | Buy |
1,414
+1
| +0.1% | +$184 | 0.02% | 560 |
|
|
2025
Q4 | $249K | Sell |
1,413
-80
| -5% | -$13.1K | 0.01% | 571 |
|
|
2025
Q3 | $225K | Sell |
1,493
-134
| -8% | -$18.1K | 0.01% | 645 |
|
|
2025
Q2 | $204K | Buy |
1,627
+3
| +0.2% | +$374 | 0.01% | 644 |
|
|
2025
Q1 | $222K | Sell |
1,624
-31
| -2% | -$4.43K | 0.02% | 606 |
|
|
2024
Q4 | $253K | Sell |
1,655
-4
| -0.2% | -$675 | 0.02% | 557 |
|
|
2024
Q3 | $322K | Sell |
1,659
-9
| -0.5% | -$1.88K | 0.03% | 498 |
|
|
2024
Q2 | $387K | Buy |
1,668
+3
| +0.2% | +$652 | 0.03% | 395 |
|
|
2024
Q1 | $359K | Sell |
1,665
-9
| -0.5% | -$2.11K | 0.03% | 417 |
|
|
2023
Q4 | $433K | Buy |
1,674
+27
| +2% | +$6.63K | 0.04% | 365 |
|
|
2023
Q3 | $423K | Buy |
1,647
+112
| +7% | +$30K | 0.05% | 351 |
|
|
2023
Q2 | $437K | Sell |
1,535
-62
| -4% | -$18.5K | 0.05% | 337 |
|
|
2023
Q1 | $444K | Sell |
1,597
-49
| -3% | -$13.6K | 0.05% | 331 |
|
|
2022
Q4 | $456K | Sell |
1,646
-851
| -34% | -$240K | 0.06% | 298 |
|
|
2022
Q3 | $667K | Sell |
2,497
-642
| -20% | -$136K | 0.09% | 225 |
|
|
2022
Q2 | $640K | Sell |
3,139
-261
| -8% | -$53.4K | 0.08% | 246 |
|
|
2022
Q1 | $716K | Buy |
3,400
+157
| +5% | +$34.1K | 0.08% | 241 |
|
|
2021
Q4 | $778K | Buy |
3,243
+248
| +8% | +$63.8K | 0.09% | 213 |
|
|
2021
Q3 | $848K | Sell |
2,995
-24
| -0.8% | -$7.87K | 0.11% | 194 |
|
|
2021
Q2 | $1.04M | Sell |
3,019
-885
| -23% | -$268K | 0.14% | 161 |
|
|
2021
Q1 | $1.09M | Buy |
3,904
+108
| +3% | +$29.1K | 0.18% | 133 |
|
|
2020
Q4 | $929K | Sell |
3,796
-357
| -9% | -$92.1K | 0.18% | 133 |
|
|
2020
Q3 | $1.18M | Buy |
4,153
+1,075
| +35% | +$300K | 0.27% | 101 |
|
|
2020
Q2 | $824K | Buy |
3,078
+337
| +12% | +$101K | 0.2% | 126 |
|
|
2020
Q1 | $867K | Buy |
2,741
+546
| +25% | +$166K | 0.26% | 105 |
|
|
2019
Q4 | $651K | Sell |
2,195
-82
| -4% | -$22.8K | 0.16% | 148 |
|
|
2019
Q3 | $530K | Buy |
2,277
+20
| +0.9% | +$4.66K | 0.15% | 164 |
|
|
2019
Q2 | $528K | Buy |
2,257
+14
| +0.6% | +$3.23K | 0.15% | 161 |
|
|
2019
Q1 | $530K | Sell |
2,243
-230
| -9% | -$72.4K | 0.14% | 156 |
|
|
2018
Q4 | $744K | Buy |
2,473
+5
| +0.2% | +$1.6K | 0.21% | 107 |
|
|
2018
Q3 | $872K | Sell |
2,468
-110
| -4% | -$37.9K | 0.22% | 107 |
|
|
2018
Q2 | $748K | Hold |
2,578
| – | – | 0.18% | 129 |
|
|
2018
Q1 | $706K | Buy |
2,578
+77
| +3% | +$23.9K | 0.17% | 140 |
|
|
2017
Q4 | $797K | Buy |
+2,501
| New | +$802K | 0.19% | 105 |
|
Other funds holding BIIB
AIM
AAMU
Verdence Capital Advisors's BIIB Position: Q2 2026 in Review
Verdence Capital Advisors increased its Biogen (BIIB) stake by 0.28% in Q2 2026, buying an estimated $765 and bringing the position to 1,418 shares worth $306K. The position accounts for 0.02% of the portfolio, ranked #537.
Verdence Capital Advisors first reported a position in BIIB in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.18M in Q3 2020. 430 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Verdence Capital Advisors held 1,418 shares of Biogen worth $306K as of Q2 2026.
- Verdence Capital Advisors bought 4 Biogen shares in Q2 2026, an estimated $765.
- Biogen made up 0.02% of Verdence Capital Advisors's portfolio in Q2 2026, its #537 holding.
- Verdence Capital Advisors first reported a position in Biogen in Q4 2017 and has held it in 35 quarters since.
- Verdence Capital Advisors's Biogen position peaked at $1.18M in Q3 2020.
- 430 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Verdence Capital Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.